Evidence map›Paper›PMID 41709080›Full record

ArticleCancer medicine2026

Establishment of a Large-Scale PDX Library of Head and Neck Cancers for Functional Precision Oncology.

Hisano Yanagi, Tomoki Kuki, Tetsuya Takimoto, Miki Takabayashi, Seiji Yamada, Chikako Yagi, Yoshitake Kiryu, Maki Kurimoto, Miho Ishikawa, Arisa Yoshida and 8 more

Abstract read
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hisano YanagiDepartment of Medical Oncology, Fujita Health University School of Medicine, Toyoake, Japan.
Tomoki KukiDepartment of Otolaryngology-Head and Neck Surgery, Fujita Health University School of Medicine, Toyoake, Japan.
Tetsuya TakimotoOncology Innovation Center, Fujita Health University, Toyoake, Japan.
Miki TakabayashiDepartment of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Seiji YamadaOncology Innovation Center, Fujita Health University, Toyoake, Japan.
Chikako YagiDepartment of Otolaryngology-Head and Neck Surgery, Fujita Health University School of Medicine, Toyoake, Japan.
Yoshitake KiryuDepartment of Otolaryngology-Head and Neck Surgery, Fujita Health University School of Medicine, Toyoake, Japan.
Maki KurimotoOncology Innovation Center, Fujita Health University, Toyoake, Japan.
Miho IshikawaOncology Innovation Center, Fujita Health University, Toyoake, Japan.
Arisa YoshidaOncology Innovation Center, Fujita Health University, Toyoake, Japan.
Yasuyoshi MizutaniDepartment of Molecular Oncology, Fujita Health University School of Medicine, Toyoake, Japan.
Atsushi EnomotoDepartment of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Motoshi SuzukiDepartment of Molecular Oncology, Fujita Health University School of Medicine, Toyoake, Japan.ORCID https://orcid.org/0000-0003-0682-5006
Kenji KawadaDepartment of Medical Oncology, Fujita Health University School of Medicine, Toyoake, Japan.
Hisayuki KatoDepartment of Otolaryngology-Head and Neck Surgery, Fujita Health University School of Medicine, Toyoake, Japan.
Ichiro TateyaDepartment of Otolaryngology-Head and Neck Surgery, Fujita Health University School of Medicine, Toyoake, Japan.
Hideyuki SayaOncology Innovation Center, Fujita Health University, Toyoake, Japan.
Takashi WatanabeOncology Innovation Center, Fujita Health University, Toyoake, Japan.ORCID https://orcid.org/0000-0002-9015-5246

Funding

Japan Society for the Promotion of Science 23H00410Japan Society for the Promotion of Science 23K06660Japan Society for the Promotion of Science 23K08948Japan Society for the Promotion of Science 23K15897Takeda Science Foundation
6 · The paper itself

Abstract

backgroundPrecision oncology leverages the molecular and genetic characteristics of tumors to enable accurate diagnosis and effective treatment selection. However, recent clinical trials have highlighted the limitations of current approaches and underscored the need to integrate static molecular profiling with functional analyses using patient-derived xenograft (PDX) models-particularly for cancers such as head and neck cancer (HNC), where driver mutations are rare and prognosis remains poor.

methodsHere, we aimed to establish a large-scale PDX library for HNC, termed the Fujita Xenograft Library (FXeL), annotated with detailed clinical information. Since 2022, tumor specimens from over 100 surgical cases at Fujita Health University Hospital have been transplanted into immunodeficient mice, resulting in the successful establishment of 62 PDX models.

resultsAdvanced clinical stage was significantly associated with successful engraftment, and serial passaging led to progressively accelerated tumor growth. Comparative analyses of genomic profiles between patient tumors and PDXs demonstrated that major cancer-related mutations were largely preserved in PDXs, while clonal selection and evolution occurred during engraftment. Histopathological features, including keratinization and nuclear atypia, were retained, whereas stromal components such as cancer-associated fibroblasts exhibited compositional shifts. Furthermore, drug sensitivity assays revealed that PDX responses to cisplatin (CDDP) closely mirrored the clinical outcomes of the corresponding patients.

conclusionsThe FXeL represents a robust and scalable platform for investigating HNC biology and therapeutic response. Despite limitations such as stromal remodeling and the absence of an immune microenvironment, these models provide valuable translational insights and support the advancement of functional precision oncology.

Indexed as

Head and Neck NeoplasmsPrecision MedicineAnimalsAntineoplastic AgentsFemaleHumansMaleMiceMiddle AgedMutationXenograft Model Antitumor AssaysAntineoplastic Agentschemotherapy sensitivityfunctional precision oncologyhead and neck cancerpatient‐derived xenograft (PDX) librarypreclinical mouse model

Identifiers

PMID41709080
PMCPMC12916448

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.